CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
Yu LiC Cameron Yin

Abstract

Follicular lymphoma is a low-grade B-cell lymphoma of germinal center B-cell origin that typically lacks CD5 expression. We describe the clinicopathologic features of 88 cases of CD5+ follicular lymphoma (53 men, 35 women; median age, 60 years; range, 31-86). Follicular lymphoma was diagnosed initially in lymph nodes in 66 and extranodal sites in 22 patients. Eighty-one patients had lymphadenopathy, 66 had more than one involved site, 46 had bone marrow involvement, and 7 had splenomegaly. Staging information was available for 84 patients: 52 stage IV, 18 stage III, 12 stage II, and 2 stage I. Sixty-one cases were grade 1 or 2 and 27 were grade 3. The median proliferation index (Ki-67) was 30%. CD5 expression was detected by flow cytometry in 69, immunohistochemistry in 8, and both methods in 11 cases. The presence of t(14;18)(q32;q21)/IGH-BCL2 or other BCL2 translocation was detected in 28/44 (64%) cases. A total of 38 (43%) patients also had diffuse large B-cell lymphoma, concurrent with (n=20), subsequent to (n=13), or developing before CD5+ follicular lymphoma (n=5). All patients received chemotherapy; 12 also received stem-cell transplantation. With a median follow-up of 55 months (range, 0.5-207), 15 patients died, 46 wer...Continue Reading

References

Jan 1, 1988·Annals of Internal Medicine·E G LevineC D Bloomfield
Oct 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J GallagherT A Lister
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y BastionB Coiffier
Jun 24, 1999·Immunology Today·P YouinouP M Lydyard
Aug 11, 2000·Applied Immunohistochemistry & Molecular Morphology : AIMM·C C ChenS H Swerdlow
May 8, 2001·American Journal of Clinical Pathology·J J TiesingaG Inghirami
Apr 10, 2002·American Journal of Clinical Pathology·Jerry W PickeringHarry R Hill
Oct 12, 2002·American Journal of Clinical Pathology·Todd S BarryStefania Pittaluga
Feb 13, 2003·American Journal of Clinical Pathology·Henry Y DongJames Weisberger
Jan 21, 2004·Genes, Chromosomes & Cancer·Mattias HöglundDouglas E Horsman
Feb 14, 2004·Immunological Reviews·Rita CarsettiHedda Wardmann
Mar 4, 2005·American Journal of Clinical Pathology·C Cameron YinL Jeffrey Medeiros
Oct 24, 2006·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·C Cameron YinLynne V Abruzzo
Apr 19, 2011·Internal Medicine·Yasunobu SekiguchiMasaaki Noguchi
May 15, 2013·Methods in Molecular Biology·C Cameron Yin, Rajyalakshmi Luthra
Oct 15, 2013·American Journal of Clinical Pathology·Jesse Manuel JasoL Jeffrey Medeiros
Apr 24, 2014·Internal Medicine Journal·E MaysonK Cartwright

❮ Previous
Next ❯

Citations

Oct 21, 2015·Virchows Archiv : an International Journal of Pathology·Luc XerriGerman Ott
Sep 13, 2016·Pediatric Blood & Cancer·Lei ChenKenichi Koike
Oct 25, 2016·The American Journal of Surgical Pathology·Zhihong HuShimin Hu
Apr 7, 2020·Journal of Clinical and Experimental Hematopathology : JCEH·Tadashi YoshinoYasuharu Sato
Jul 25, 2019·Current Hematologic Malignancy Reports·Narittee Sukswai, Joseph D Khoury
May 3, 2019·Oncology Reviews·Kaveh JasebNajmaldin Saki
Dec 29, 2020·Clinical Case Reports·Sujal I ShahDavid T Yang
Apr 7, 2021·American Journal of Clinical Pathology·Matthew T YeM James You
Nov 20, 2021·Journal of Cutaneous Pathology·Jack LeeAlejandro A Gru

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.